skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The pharmaceutical industry is ripe for the picking with a virtual smorgasbord of unpartnered product opportunities in our 2015 update. As smaller biotech and pharma companies continue to advance their pipelines to meet unmet needs they are faced with the burning question of where to allocate their limited financial resources. Should these companies continue to spend money to further develop their pipeline candidates to market or should they out-license drugs further along in development and go back to the drawing board to identify new products?





電話:+81 (0)3 6273 4260